Cargando…
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...
Autores principales: | Fujiwara, Atsushi, Yoshida, Masamichi, Fujimoto, Hajime, Nakahara, Hiroki, Ito, Kentaro, Nishihama, Kota, Yasuma, Taro, Hataji, Osamu, Taguchi, Osamu, D’Alessandro-Gabazza, Corina N., Gabazza, Esteban C., Kobayashi, Tetsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cognizant Communication Corporation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844677/ https://www.ncbi.nlm.nih.gov/pubmed/29321093 http://dx.doi.org/10.3727/096504018X15151523767752 |
Ejemplares similares
-
Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020) -
Factors leading to failure to diagnose pulmonary malignant tumors using endobronchial ultrasound with guide sheath within the target lesion
por: Nishii, Yoichi, et al.
Publicado: (2019) -
Renal Injury during Long-Term Crizotinib Therapy
por: Yasuma, Taro, et al.
Publicado: (2018) -
Identification of Halophilic Microbes in Lung Fibrotic Tissue by Oligotyping
por: D’Alessandro-Gabazza, Corina N., et al.
Publicado: (2018) -
Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer
por: Nakamura, Yuki, et al.
Publicado: (2018)